FDA Approves Expanded Liquid Biopsy Panel - Summary - MDSpire

FDA Approves Expanded Liquid Biopsy Panel

  • By

  • Kathryn Wighton

  • May 20, 2026

Share

Objective:

To inform about the FDA approval of the Guardant360 Liquid CDx assay for advanced cancer treatment selection.

Key Findings:
  • The assay is the largest FDA-approved liquid biopsy panel.
  • It combines genomic and epigenomic profiling to improve tumor detection.
  • The platform is based on AI-enabled technology and supports various cancer care stages.
Interpretation:

This approval signifies a significant advancement in precision oncology, providing clinicians with timely and comprehensive information for treatment decisions.

Limitations:
  • The assay's effectiveness may vary based on individual patient factors.
  • Coverage by insurers may not be universal across all regions.
Conclusion:

The Guardant360 Liquid CDx assay represents a major step forward in liquid biopsy technology, potentially improving treatment outcomes for patients with advanced cancers.

Original Source(s)

FDA Approves Expanded Liquid Biopsy Panel

  • by Kathryn Wighton

  • May 20, 2026

Related Content

Digital Pathology: the Great Translation Debate

Conference discussions highlighted collaboration, resilience, and the realities of AI adoption in pathology labs

DNA Quality Outweighs Bone Source

Background DNA burden was more strongly associated with sequencing profile completeness than bone source in unidentified human remains.

Could Digital Twins Forecast Forensic Risk?

Researchers outline a proposed three-level framework spanning patient monitoring, ward operations, and forensic system planning.